SBIR-STTR Award

Cell Therapy for Temporomandibular Joint Repair
Award last edited on: 5/14/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIDCR
Total Award Amount
$95,139
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
David Fink

Company Information

Osiris Therapeutics Inc

7015 Albert Einstein Drive
Columbia, MD 21046
   (443) 545-1800
   osiris@osiristx.com
   www.osiristx.com
Location: Single
Congr. District: 03
County: Howard

Phase I

Contract Number: 1R43DE011505-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1995
Phase I Amount
$95,139
In the context of skeletal tissue repair, Regenerative Tissue Therapy is the local application of autologous (host-derived) cells to promote reconstruction of tissue defects caused by trauma, disease or surgical procedures. The objective of the Regenerative Tissue Therapy approach is to deliver high densities of repair-competent cells to the defect site in a format that optimizes both initial wound mechanics and eventual neotissue production. We are a development-stage company engaged in the development of cellular transplants and cell-matrix products for the treatment of soft tissue and bone disorders. These cellular transplants and cell-matrix products are derived from the isolation, purification and propagation of autologous human Mesenchymal Stem Cells (MSCs), the progenitor cells which give rise to all mesodermal tissues such as cartilage, ligament, tendon and muscle. Phase I will demonstrate the efficacy of a proprietary cell delivery concept for autologous MSC therapy in short-term rabbit temporomandibular (TMJ) disc implants.National Institute of Dental Research (NIDR)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----